PrREXULTI® is indicated for use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode.
CANMAT MDD Guidelines resource
A tool that includes the treatment algorithm for managing inadequate response to an antidepressant.
Additional resources
A tool that outlines the study design, efficacy and safety data for the PYXIS study, the pivotal trial for MDD for REXULTI.
A comprehensive tool that outlines a patient profile and the key efficacy and safety data for the MDD indication for REXULTI.
A card that outlines the dosing information for MDD.
Provide your patients with educational material
An informative brochure for patients initiated on REXULTI that includes information on depression, REXULTI, and answers to frequently asked questions.
A 4-week journal to help patients track their symptoms, lifestyle goals, and other wellness parameters.
(myrexultijourney.ca)
A gated website for REXULTI patients that helps them learn about depression and their treatment with REXULTI, as well as providing lifestyle tips and resources to support their treatment.
PrREXULTI® is indicated for the symptomatic management of agitation associated with Alzheimer's dementia (AAD) in patients with aggressive behaviour, unresponsive to non-pharmacological approaches.
A comprehensive tool that outlines a patient profile and the key efficacy and safety data for the AAD indication for REXULTI.
Additional resource
A handy card that includes the dosing information for all REXULTI indications.